EODData

MEMBERSHIP REGISTER LOG IN

FRA, ENM: CASI PHARMAC. NEW O.N.

08 Sep 2025
LAST:

1.540

CHANGE:
 0.00		OPEN:
1.540		HIGH:
1.540		ASK:
0.000		VOLUME:
0
CHG(%):
0.00		PREV:
1.540		LOW:
1.540		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
08 Sep 251.5401.5401.5401.5400
05 Sep 251.5401.5401.5401.5400
02 Sep 251.5401.5401.5401.5400
01 Sep 251.5401.5401.5401.5400
29 Aug 251.5401.5401.5401.5400
28 Aug 251.5401.5401.5401.5400
27 Aug 251.5401.5401.5401.5400
26 Aug 251.5401.5401.5401.5400
25 Aug 251.5401.5401.5401.5400
22 Aug 251.5401.5401.5401.5400

COMPANY PROFILE

Name:CASI PHARMAC. NEW O.N.
About:CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Sector:Healthcare
Industry:Biotechnology
ISIN:US14757U2087

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.54
MA10:1.54
MA20:1.54
MA50:1.54
MA100:1.54
MA200:1.54
Week High:1.54
Week Low:1.54
Month High:1.54
Month Low:1.54
Year High:1.56
Year Low:1.53
Volatility:11.35

RECENT SPLITS

Date Ratio
02 Jun 20221-10